We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+5.98%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$5.26B
AUM Growth
+$740M
Cap. Flow
+$520M
Cap. Flow %
9.89%
Top 10 Hldgs %
40.34%
Holding
110
New
23
Increased
31
Reduced
29
Closed
25

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$178M
2
AGN
Allergan plc
AGN
+$168M
3
GILD icon
Gilead Sciences
GILD
+$89.7M
4
BABA icon
Alibaba
BABA
+$67.2M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$66.5M

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$93.9M
2
BPMC
Blueprint Medicines
BPMC
+$77.2M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$73.7M
4
PFE icon
Pfizer
PFE
+$50.2M
5
ELV icon
Elevance Health
ELV
+$42.9M

Sector Composition

Rank Sector Weight
1 Healthcare 55.27%
2 Technology 8.75%
3 Communication Services 4%
4 Consumer Discretionary 3.22%
5 Financials 2.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TCOM icon
51
Trip.com Group
TCOM
$28.5B
$34.2M 0.65%
927,160
+547,650
+144% +$21.6M
CTLT
52
DELISTED
CATALENT, INC.
CTLT
$33.4M 0.64%
+617,019
New +$28.3M
XNTK icon
53
CALL
State Street SPDR NYSE Technology ETF
XNTK
$2B
$33.2M 0.63%
378,000
-2,288,000
-86% -$165M
AMGN icon
54
CALL
Amgen
AMGN
$212B
$32.5M 0.62%
+176,600
New +$31.6M
CHRS icon
55
Coherus Oncology
CHRS
$222M
$32.2M 0.61%
1,457,985
+510,924
+54% +$8.87M
PCRX icon
56
Pacira BioSciences
PCRX
$1.05B
$31.9M 0.61%
734,346
+452,149
+160% +$19.2M
FATE icon
57
Fate Therapeutics
FATE
$270M
$31.4M 0.6%
1,547,730
+266,194
+21% +$4.8M
THC icon
58
Tenet Healthcare
THC
$22.6B
$30.7M 0.58%
+1,484,683
New +$34.2M
MSGS icon
59
Madison Square Garden
MSGS
$9.58B
$28.7M 0.54%
143,520
-14,710
-9% -$3.13M
MMSI icon
60
Merit Medical Systems
MMSI
$4.67B
$26.5M 0.5%
444,187
-533,126
-55% -$30.6M
COUP
61
DELISTED
Coupa Software Incorporated
COUP
$23.7M 0.45%
186,935
+6,013
+3% +$645K
RVTY icon
62
Revvity
RVTY
$12.4B
$20.6M 0.39%
213,370
-259,286
-55% -$24.2M
ICLR icon
63
Icon
ICLR
$13.9B
$20.1M 0.38%
+130,375
New +$18.3M
PRNB
64
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$19.7M 0.37%
+594,516
New +$18.6M
AVTR icon
65
Avantor
AVTR
$8.48B
$19.1M 0.36%
+999,873
New +$17.8M
CSII
66
DELISTED
Cardiovascular Systems, Inc.
CSII
$18.3M 0.35%
425,315
-21,606
-5% -$839K
FICO icon
67
Fair Isaac
FICO
$31B
$17.7M 0.34%
56,215
-30,041
-35% -$8.71M
LAB icon
68
Standard BioTools
LAB
$311M
$17M 0.32%
1,376,257
-65,106
-5% -$829K
ONCE
69
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$15.8M 0.3%
154,599
-61,222
-28% -$6.61M
DBX icon
70
Dropbox
DBX
$7.48B
$15.2M 0.29%
608,087
-554,620
-48% -$12.8M
UNH icon
71
UnitedHealth
UNH
$389B
$15M 0.28%
61,321
-390,368
-86% -$93.9M
KRTX
72
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$14.2M 0.27%
+773,031
New +$15.5M
QURE icon
73
uniQure
QURE
$2.52B
$13.7M 0.26%
174,754
-242,108
-58% -$15.4M
INGN icon
74
Inogen
INGN
$174M
$9.42M 0.18%
+141,077
New +$10.7M
EQ icon
75
Equillium
EQ
$147M
$7.99M 0.15%
1,410,832
-36,140
-2% -$227K
1 2
3
4 5

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return

PFM Health Sciences's Q2 2019 Portfolio in Review

As of Q2 2019, PFM Health Sciences held 110 positions worth $5.26B, up 16% from $4.52B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

PFM Health Sciences deployed $520M of net new capital in Q2 2019, opening 23 new positions and adding to 31 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 2,079,388 shares worth $178M.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, up from 55% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was UnitedHealth, an estimated $93.9M trimmed.

  • PFM Health Sciences's largest Q2 2019 buy was BioMarin Pharmaceuticals: 2,079,388 shares worth $178M.
  • PFM Health Sciences added most to Allergan plc in Q2 2019, an estimated $168M increase.
  • PFM Health Sciences's biggest Q2 2019 reduction was UnitedHealth, cutting an estimated $93.9M.
  • PFM Health Sciences fully exited Blueprint Medicines in Q2 2019, selling an estimated $77.2M.
  • PFM Health Sciences's ten largest holdings make up 40% of its $5.26B portfolio in Q2 2019.
  • PFM Health Sciences opened 23 new positions and closed 25 in Q2 2019.
  • PFM Health Sciences's portfolio value rose 16% quarter-over-quarter to $5.26B.

Based on PFM Health Sciences's 13F filing for Q2 2019, filed 14 Aug 2019.